Oct 9, 2026
Poster · Psoriasis · Phase 2 / Phase 3
Prifemilast, an Oral Phosphodiesterase 4B (PDE4B)-Selective Inhibitor, Demonstrates Rapid and Durable Efficacy With a Favorable Tolerability and Safety Profile in Moderate to Severe Plaque Psoriasis: Results From Phase 2 and 3 Trials
26th Annual Fall Clinical Dermatology Conference · October 8–11, 2026 · Las Vegas, NV
View poster →
Oct 9, 2026
Poster · Psoriasis · Phase 3 head-to-head
Superior Efficacy of the Oral Phosphodiesterase 4B (PDE4B)-Selective Inhibitor Prifemilast Versus Apremilast in Moderate to Severe Plaque Psoriasis: Top-Line Results of a Head-to-Head Phase 3 Trial
26th Annual Fall Clinical Dermatology Conference · October 8–11, 2026 · Las Vegas, NV
View poster →
Prifemilast is an investigational agent and is not approved for use by any regulatory authority.